Treatment of joint pain
This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).
1. A method for treating osteoarthritis, comprising administering to an osteoarthritic joint in a subject a pharmaceutical composition that contains a therapeutically effective amount of a senolytic agent defined as (4-[(4S,5R)-4,5 bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone) (Nutlin-3A) or a salt thereof, in a pharmaceutically compatible excipient.
2. The method of claim 1 , wherein the senolytic agent is compounded in a sustained release formulation that comprises a gel, a polymeric matrix, or a microparticle.
3. The method of claim 1 , wherein the senolytic agent is administered to the osteoarthritic joint as a single dose, followed by a non-treatment interval of at least two weeks.
4. The method of claim 1 , wherein administration of the pharmaceutical composition inhibits erosion of a proteoglycan layer in the osteoarthritic joint.
5. The method of claim 1 , wherein administration of the pharmaceutical composition promotes production of collagen Type II in the osteoarthritic joint.
6. The method of claim 1 , wherein administration of the pharmaceutical composition relieves symptoms of osteoarthritis being experienced by the subject in the joint.
7. The method of claim 1 , wherein administration of the pharmaceutical composition relieves pain being experienced by the subject in the joint.
8. The method of claim 1 , wherein the senolytic agent is compounded in a formulation that includes a hyaluronan.